From Stamp Trading to Nasdaq: The Journey of Dr. Ethan Shen
- 2 days ago
- 2 min read
From Stamp Trading to Nasdaq | The Journey of Dr. Ethan Shen and YD Bio
What kind of force can take a boy selling stamps and betel nuts in Yunlin to the Nasdaq stage?
Born in 1976, Dr. Ethan Shen grew up in a humble family. His father was a pharmacy apprentice, and his mother supported the household. To ease the financial burden, he sold betel nuts and herbal tea, and worked night shifts at a pizza shop.
In third grade, his family moved to Sanchong, living in a small and crowded space. Rather than limiting him, these hardships shaped his resilience.
Even in grade school, he demonstrated strong entrepreneurial instincts. Noticing his classmates’ interest in stamp collecting, he sourced stamps from Ximending and resold them—his first “business.”
While studying, he worked nights to support himself. After graduation, he joined Novartis, gaining firsthand insight into how healthcare connects with markets and global resources.
Years later, he founded YD Bio and successfully led the company to a Nasdaq listing on August 29, 2025 (YDES, YDESW), focusing on:
DNA methylation–based cancer diagnostics
Stem cell and exosome ophthalmic therapies
Clinical trial services
To investors, he is a business leader. To the world, a success story in the capital markets.
But to Dr. Shen, his journey reflects a deeper belief: "Life is not confined by reality—it can be extraordinary."
We may not choose where we start, but resilience and courage can take us anywhere.
About YD Bio Limited
YD Bio Ltd is a U.S.-anchored public biotechnology company building an integrated healthcare platform across regulated diagnostics, clinical services, and commercial healthcare markets. The Company operates DNA methylation–based oncology testing programs in the United States under an LDT-first strategy and provides compliant life science distribution and clinical trial supply chain services to pharmaceutical and biotechnology partners. In addition, YD Bio Ltd maintains regulated ocular health commercialization operations and a consumer health distribution platform in Asia. Through strategic partnerships and scalable execution capabilities, the Company advances biomedical innovation with real-world clinical and commercial impact. For more information, visit ir.ydesgroup.com and follow the Company on Facebook, X, Threads, Instagram and LinkedIn.